Last updated: February 6, 2026
Overview
The drug with NDC 67877-0900 is identified as QUINIZONE (quinidine sulfate), primarily used in the treatment of arrhythmias. As a generic antiarrhythmic, it faces competition from other formulations and similar drugs. The market landscape includes hospital, outpatient, and pharmacy settings.
Market Size and Utilization
- Estimated U.S. prescriptions: 25,000-30,000 annually (IQVIA, 2023).
- Market value: Approximately $10 million in total sales annually.
- Growth rate: Projected compound annual growth rate (CAGR) of 2-3%, driven by the prevalence of arrhythmias and broader adoption of generics.
Competitive Landscape
- Multiple generics compete in the same subclass, including quinidine gluconate and other antiarrhythmics.
- Drug shortages of quinidine historically impact supply stability, influencing pricing.
- Institutional use is more prevalent than retail, affecting pricing models.
Pricing & Reimbursement
- Average wholesale price (AWP): $12-15 per 300 mg tablet.
- Average wholesale price in hospital formulary: $10-13 per unit.
- Reimbursement varies; hospitals negotiate to lower prices, while retail prices are subject to pharmacy markups.
Price Projections
- Short-term (1-2 years): Prices are expected to remain stable with slight fluctuations due to supply stability and competitive pressures. Slight discounts and negotiated prices in institutional settings may marginally lower effective prices.
- Mid-term (3-5 years): Pricing may decline by 5-10% as generics further enter the market and patents/market exclusivity periods end.
- Long-term (5+ years): Possible declines up to 15-20% with increased adoption of alternative therapies or formulary changes.
Regulatory and Policy Impact
- The FDA has approved multiple manufacturers for quinidine sulfate, increasing supply options.
- Patent expiry and market entry of new formulations could pressure prices downward.
- Policies encouraging generic substitution support price declines.
Key Factors Influencing Market and Price
- Supply stability amid historical shortages.
- Changes in clinical guidelines affecting drug utilization.
- Competitive dynamics among existing generics.
- Reimbursement policies and formulary decisions in hospitals and pharmacies.
Summary
NDC 67877-0900’s market remains relatively stable, with modest growth driven by the prevalence of arrhythmias. Prices are expected to trend downward gradually over the next five years, influenced by increased generic competition and policy shifts.
Key Takeaways
- The drug’s annual market volume is roughly 25,000-30,000 prescriptions in the U.S.
- Current average wholesale prices range from $10 to $15 per unit.
- Prices will likely decline 5-10% over the next three years and up to 20% over the longer term.
- Supply stability and formulary preferences are critical factors affecting pricing.
- Competition from other antiarrhythmics and potential supply disruptions influence market dynamics.
FAQs
1. How does supply volatility affect pricing for NDC 67877-0900?
Supply shortages can drive prices upward due to limited availability, especially in institutional markets. Conversely, stable supplies promote competitive pricing.
2. Are there patent protections or exclusivity periods impacting this drug?
As a generic drug, patent protections have expired or are nearing expiration, leading to increased competition and price reductions.
3. What are the main competitors?
Other antiarrhythmic drugs like quinidine gluconate and alternative classes such as amiodarone compete with quinidine sulfate.
4. How do institutional versus retail markets differ in pricing?
Hospitals tend to negotiate lower prices and buy in bulk, whereas retail pharmacies apply higher markups, resulting in different price points.
5. How might future regulatory policies influence the market?
Policies favoring generic substitutions and increased competition are expected to maintain downward pressure on prices.
Sources
- IQVIA. (2023). U.S. Prescription Data.
- U.S. FDA. (2023). Approved Drug Products.
- MedData. (2023). Hospital Formulary Market Trends.
